CRISPR Therapeutics AG (CRSP)
51.44
+0.68
(+1.34%)
USD |
NASDAQ |
Nov 04, 13:19
CRISPR Therapeutics Net Income (Quarterly): -126.41M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -126.41M |
| March 31, 2024 | -116.59M |
| December 31, 2023 | 89.35M |
| September 30, 2023 | -112.15M |
| June 30, 2023 | -77.74M |
| March 31, 2023 | -53.06M |
| December 31, 2022 | -110.58M |
| September 30, 2022 | -174.55M |
| June 30, 2022 | -185.83M |
| March 31, 2022 | -179.22M |
| December 31, 2021 | -141.25M |
| September 30, 2021 | -127.15M |
| June 30, 2021 | 759.22M |
| March 31, 2021 | -113.16M |
| December 31, 2020 | -107.04M |
| September 30, 2020 | -92.44M |
| June 30, 2020 | -79.66M |
| March 31, 2020 | -69.73M |
| Date | Value |
|---|---|
| December 31, 2019 | 30.54M |
| September 30, 2019 | 138.42M |
| June 30, 2019 | -53.70M |
| March 31, 2019 | -48.41M |
| December 31, 2018 | -47.59M |
| September 30, 2018 | -50.71M |
| June 30, 2018 | -38.38M |
| March 31, 2018 | -28.30M |
| December 31, 2017 | 0.141M |
| September 30, 2017 | -24.71M |
| June 30, 2017 | -22.32M |
| March 31, 2017 | -21.48M |
| December 31, 2016 | 17.10M |
| September 30, 2016 | -14.69M |
| June 30, 2016 | -17.16M |
| March 31, 2016 | -8.442M |
| December 31, 2015 | -12.29M |
| September 30, 2015 | -6.354M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-185.83M
Minimum
Jun 2022
759.22M
Maximum
Jun 2021
-51.97M
Average
-110.58M
Median
Dec 2022
Net Income (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | -3.594B |
| AC Immune SA | -25.17M |
| Addex Therapeutics Ltd | 14.24M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | -16.68M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 151.26M |
| EPS Diluted (Quarterly) | -1.49 |
| Enterprise Value | 3.839B |
| Earnings Yield | -6.22% |
| Normalized Earnings Yield | -3.752 |